Valanafusp alfa  (Synonyms: AGT-181; HIRMAb-IDUA)

Valanafusp alfa (AGT-181) is a chimeric monoclonal antibody that fuses human α-L-iduronidase (IDUA) and targets the human insulin receptor (HIR). Valanafusp alfa has brain penetrating properties, making it useful for research on mucopolysaccharidosis type I (MPS I)^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Fusion Protein

Valanafusp alfa (HIRMAb-IDUA) 与 HIR 胞外结构域 (ECD) 结合，EC₅₀ 为 0.93±0.07 nM^[2]。
Valanafusp alfa (HIRMAb-IDUA) (0.3 μg/mL; 48 h) 与健康成纤维细胞相比，可使 Hurler 成纤维细胞中的糖氨基聚糖积累减少 70%^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) 慢性给药在所有剂量下都具有极好的安全性，并且对血浆或脑脊液的血糖控制没有影响^[1]。
Valanafusp alfa (AGT-181) (0.2-20 mg/kg; IV) 在 Rhesus monkeys 体内稳定，清除率快，分布量大^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1815583-32-4

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• [1]. Boado RJ, et al. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J Biotechnol. 2009 Oct 26;144(2):135-41.  [Content Brief]

  [2]. Boado RJ, et al. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng. 2008 Feb 1;99(2):475-84.  [Content Brief]